Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2003

Open Access 01-12-2003 | Review

Lipoxygenase and cyclooxygenase metabolism: new insights in treatment and chemoprevention of pancreatic cancer

Authors: Xian-Zhong Ding, Rene Hennig, Thomas E Adrian

Published in: Molecular Cancer | Issue 1/2003

Login to get access

Abstract

The essential fatty acids, linoleic acid and arachidonic acid play an important role in pancreatic cancer development and progression. These fatty acids are metabolized to eicosanoids by cyclooxygenases and lipoxygenases. Abnormal expression and activities of both cyclooxygenases and lipoxygenases have been reported in pancreatic cancer. In this article, we aim to provide a brief summary of (1) our understanding of the roles of these enzymes in pancreatic cancer tumorigenesis and progression; and (2) the potential of using cyclooxygenase and lipoxygenase inhibitors for pancreatic cancer treatment and prevention.
Literature
1.
Lipkin M, Reddy B, Newmark H, Lamprecht SA: Dietary factors in human colorectal cancer. Annu Rev Nutr. 1999, 19: 545-586.PubMedCrossRef
2.
Willett WC: Specific fatty acids and risks of breast and prostate cancer: dietary intake. Am J Clin Nutr. 1997, 66 (6 Suppl): 1557S-1563S.PubMed
3.
Klurfeld DM, Bull AW: Fatty acids and colon cancer in experimental models. Am J Clin Nutr. 1997, 66 (6 Suppl): 1530S-1538S.PubMed
4.
Guthrie N, Carroll KK: Specific versus non-specific effects of dietary fat on carcinogenesis. Prog Lipid Res. 1999, 38: 261-271.PubMedCrossRef
5.
Funk CD: Prostaglandins and leukotrienes: advances in eicosanoid biology. Science. 2001, 294 (5548): 1871-1875.PubMedCrossRef
6.
Cao Y, Prescott SM: Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol. 2002, 190: 279-286.PubMedCrossRef
7.
Lin DT, Subbaramaiah K, Shah JP, Dannenberg AJ, Boyle JO: Cyclooxygenase-2: A novel molecular target for the prevention and treatment of head and neck cancer. Head Neck. 2002, 24: 792-799.PubMedCrossRef
8.
Howe LR, Dannenberg AJ: A role for cyclooxygenase-2 inhibitors in the prevention and treatment of cancer. Semin Oncol. 2002, 29 (3 Suppl 11): 111-119.PubMedCrossRef
9.
Ding XZ, Tong WG, Adrian TE: Cyclooxygenases and lipoxygenases as potential targets for treatment of pancreatic cancer. Pancreatology. 2001, 1 (4): 91-99.CrossRef
10.
Dannenberg AJ, Altorki NK, Boyle JO, Dang C, Howe LR, Weksler BB, Subbaramaiah K: Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol. 2001, 2: 544-551.PubMedCrossRef
11.
Gupta RA, Dubois RN: Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer. 2001, 1: 11-21.PubMedCrossRef
12.
Williams CS, Mann M, DuBois RN: The role of cyclooxygenases in inflammation, cancer, and development. Oncogene. 1999, 18: 7908-7916.PubMedCrossRef
13.
Chandrasekharan NV, Dai H, Roos KL, Evanson NK, Tomsik J, Elton TS, Simmons DL: From the Cover: COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure, and expression. PNAS. 2002, 99: 13926-13931.PubMedCentralPubMedCrossRef
14.
Iversen L, Kragballe K: Arachidonic acid metabolism in skin health and disease. Prostaglandins Other Lipid Mediat. 2000, 63: 25-42.PubMedCrossRef
15.
Yamamoto S, Suzuki H, Nakamura M, Ishimura K: Arachidonate 12-lipoxygenase isozymes. Adv Exp Med Biol. 1999, 447: 37-44.PubMedCrossRef
16.
Brash AR, Jisaka M, Boeglin WE, Chang MS: Molecular cloning of a second human 15S-lipoxygenase and its murine homologue, an 8S-lipoxygenase. Their relationship to other mammalian lipoxygenases. Adv Exp Med Biol. 1999, 447: 29-36.PubMedCrossRef
17.
Kuhn H, Borngraber S: Mammalian 15-lipoxygenases. Enzymatic properties and biological implications. Adv Exp Med Biol. 1999, 447: 5-28.PubMedCrossRef
18.
Steele VE, Holmes CA, Hawk ET, Kopelovich L, Lubet RA, Crowell JA, Sigman CC, Kelloff GJ: Lipoxygenase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev. 1999, 8: 467-83.PubMed
19.
Gunning WT, Kramer PM, Steele VE, Pereira MA: Chemoprevention by lipoxygenase and leukotriene pathway inhibitors of vinyl carbamate-induced lung tumors in mice. Cancer Res. 2002, 62: 4199-4201.PubMed
20.
Ghosh J, Myers CE: Central role of arachidonate 5-lipoxygenase in the regulation of cell growth and apoptosis in human prostate cancer cells. Adv Exp Med Biol. 1999, 469: 577-82.PubMedCrossRef
21.
Anderson KM, Seed T, Jajeh A, Dudeja P, Byun T, Meng J, Ou D, Bonomi P, Harris JE: An in vivo inhibitor of 5-lipoxygenase, MK886, at micromolar concentration induces apoptosis in U937 and CML cells. Anticancer Res. 1996, 16 (5A): 2589-99.PubMed
22.
Tang DG, Honn KV: Apoptosis of W256 carcinosarcoma cells of the monocytoid origin induced by NDGA involves lipid peroxidation and depletion of GSH: role of 12-lipoxygenase in regulating tumor cell survival. J Cell Physiol. 1997, 172 (2): 155-70.PubMedCrossRef
23.
Nie D, Che M, Grignon D, Tang K, Honn KV: Role of eicosanoids in prostate cancer progression. Cancer Metastasis Rev. 2001, 20: 195-206.PubMedCrossRef
24.
Brash AR, Jisaka M, Boeglin WE, Chang MS: Molecular cloning of a second human 15S-lipoxygenase and its murine homologue, an 8S-lipoxygenase. Their relationship to other mammalian lipoxygenases. Adv Exp Med Biol. 1999, 447: 29-36.PubMedCrossRef
25.
Iversen L, Kragballe K: Arachidonic acid metabolism in skin health and disease. Prostaglandins Other Lipid Mediat. 2000, 63: 25-42.PubMedCrossRef
26.
Muga SJ, Thuillier P, Pavone A, Rundhaug JE, Boeglin WE, Jisaka M, Brash AR, Fischer SM: 8S-lipoxygenase products activate peroxisome proliferator-activated receptor alpha and induce differentiation in murine keratinocytes. Cell Growth Differ. 2000, 11 (8): 447-54.PubMed
27.
Burger F, Krieg P, Kinzig A, Schurich B, Marks F, Furstenberger G: Constitutive expression of 8-lipoxygenase in papillomas and clastogenic effects of lipoxygenase-derived arachidonic acid metabolites in keratinocytes. Mol Carcinog. 1999, 24: 108-17.PubMedCrossRef
28.
Shureiqi I, Lippman SM: Lipoxygenase modulation to reverse carcinogenesis. Cancer Res. 2001, 61: 6307-12.PubMed
29.
Eling TE, Glasgow WC: Cellular proliferation and lipid metabolism: importance of lipoxygenases in modulating epidermal growth factor-dependent mitogenesis. Cancer Metastasis Rev. 1994, 13: 397-410.PubMedCrossRef
30.
Eling TE, Everhart AL, Angerman-Stewart J, Hui R, Glasgow WC: Modulation of epidermal growth factor signal transduction by linoleic acid metabolites. Adv Exp Med Biol. 1997, 407: 319-22.PubMedCrossRef
31.
Shureiqi I, Chen D, Lotan R, Yang P, Newman RA, Fischer SM, Lippman SM: 15-Lipoxygenase-1 mediates nonsteroidal anti-inflammatory drug-induced apoptosis independently of cyclooxygenase-2 in colon cancer cells. Cancer Res. 2000, 60: 6846-50.PubMed
32.
Profita M, Sala A, Siena L, Henson PM, Murphy RC, Paterno A, Bonanno A, Riccobono L, Mirabella A, Bonsignore G, Vignola AM: Leukotriene B4 production in human mononuclear phagocytes is modulated by interleukin-4-induced 15-lipoxygenase. J Pharmacol Exp Ther. 2002, 300: 868-75.PubMedCrossRef
33.
Shappell SB, Gupta RA, Manning S, Whitehead R, Boeglin WE, Schneider C, Case T, Price J, Jack GS, Wheeler TM, Matusik RJ, Brash AR, Dubois RN: 15S-Hydroxyeicosatetraenoic acid activates peroxisome proliferator-activated receptor gamma and inhibits proliferation in PC3 prostate carcinoma cells. Cancer Res. 2001, 61: 497-503.PubMed
34.
Anderson KE, Johnson TW, Lazovich D, Folsom AR: Association between nonsteroidal anti-inflammatory drug use and the incidence of pancreatic cancer. J Natl Cancer Inst. 2002, 94: 1168-71.PubMedCrossRef
35.
O'Neill GP, Ford-Hutchinson AW: Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett. 1993, 330: 156-60.PubMedCrossRef
36.
Tucker ON, Dannenberg AJ, Yang EK, Zhang F, Teng L, Daly JM, Soslow RA, Masferrer JL, Woerner BM, Koki AT, Fahey TJ: Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res. 1999, 59: 987-90.PubMed
37.
Okami J, Yamamoto H, Fujiwara Y, Tsujie M, Kondo M, Noura S, Oshima S, Nagano H, Dono K, Umeshita K, Ishikawa O, Sakon M, Matsuura N, Nakamori S, Monden M: Overexpression of cyclooxygenase-2 in carcinoma of the pancreas. Clin Cancer Res. 1999, 5: 2018-24.PubMed
38.
Molina MA, Sitja-Arnau M, Lemoine MG, Frazier ML, Sinicrope FA: Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res. 1999, 59 (17): 4356-4362.PubMed
39.
Yip-Schneider MT, Barnard DS, Billings SD, Cheng L, Heilman DK, Lin A, Marshall SJ, Crowell PL, Marshall MS, Sweeney CJ: Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis. 2000, 21: 139-46.PubMedCrossRef
40.
Kokawa A, Kondo H, Gotoda T, Ono H, Saito D, Nakadaira S, Kosuge T, Yoshida S: Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors. Cancer. 2001, 91: 333-8.PubMedCrossRef
41.
Merati K, said Siadaty M, Andea A, Sarkar F, Ben-Josef E, Mohammad R, Philip P, Shields AF, Vaitkevicius V, Grignon DJ, Adsay NV: Expression of inflammatory modulator COX-2 in pancreatic ductal adenocarcinoma and its relationship to pathologic and clinical parameters. Am J Clin Oncol. 2001, 24: 447-52.PubMedCrossRef
42.
Maitra A, Ashfaq R, Gunn CR, Rahman A, Yeo CJ, Sohn TA, Cameron JL, Hruban RH, Wilentz RE: Cyclooxygenase 2 expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia: an immunohistochemical analysis with automated cellular imaging. Am J Clin Pathol. 2002, 118: 194-201.PubMedCrossRef
43.
Ding XZ, Tong WG, Adrian TE: Blockade of cyclooxygenase-2 inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Anticancer Res. 2000, 20: 2625-31.PubMed
44.
Nzeako UC, Gores GJ: Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors. Cancer. 2002, 94: 1903-4.PubMedCrossRef
45.
Ding XZ, Iversen P, Cluck MW, Knezetic JA, Adrian TE: Lipoxygenase inhibitors abolish proliferation of human pancreatic cancer cells. Biochem Biophys Res Commun. 1999, 261: 218-23.PubMedCrossRef
46.
Hennig R, Ding XZ, Tong WG, Schneider MB, Standop J, Friess H, Buchler MW, Pour PM, Adrian TE: 5-Lipoxygenase and leukotriene B(4) receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue. Am J Pathol. 2002, 161: 421-8.PubMedCentralPubMedCrossRef
47.
Bleich D, Chen S, Gu JL, Nadler JL: The role of 12-lipoxygenase in pancreatic-cells (Review). Int J Mol Med. 1998, 1: 265-72.PubMed
48.
Yip-Schneider MT, Barnard DS, Billings SD, Cheng L, Heilman DK, Lin A, Marshall SJ, Crowell PL, Marshall MS, Sweeney CJ: Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis. 2000, 21: 139-46.PubMedCrossRef
49.
Anderson KM, Seed T, Meng J, Ou D, Alrefai WA, Harris JE: Five-lipoxygenase inhibitors reduce Panc-1 survival: the mode of cell death and synergism of MK886 with gamma linolenic acid. Anticancer Res. 1998, 18 (2A): 791-800.PubMed
50.
Anderson KM, Alrefai WA, Bonomi P, Dudeja P, Ou D, Anderson C, Harris JE: Altered oncogene, tumor suppressor and cell-cycle gene expression in PANC-1 cells cultured with the pleiotrophic 5-lipoxygenase inhibitor, MK886, assessed with a gene chip. Anticancer Res. 1999, 19 (5B): 3873-87.PubMed
51.
Harris JE, Alrefai WA, Meng J, Anderson KM: Five-lipoxygenase inhibitors reduce Panc-1 survival: synergism of MK886 with gamma linolenic acid. Adv Exp Med Biol. 1999, 469: 505-10.PubMedCrossRef
52.
Ding XZ, Kuszynski CA, El-Metwally TH, Adrian TE: Lipoxygenase inhibition induced apoptosis, morphological changes, and carbonic anhydrase expression in human pancreatic cancer cells. Biochem Biophys Res Commun. 1999, 266: 392-9.PubMedCrossRef
53.
Tong WG, Ding XZ, Witt RC, Adrian TE: Lipoxygenase Inhibitors Attenuate Growth of Human Pancreatic Cancer Xenografts and Induce Apoptosis through the Mitochondrial Pathway. Mol Cancer Ther. 2002, 1: 929-935.PubMed
54.
Tong WG, Ding XZ, Adrian TE: The mechanisms of lipoxygenase inhibitor-induced apoptosis in human breast cancer cells. Biochem Biophys Res Commun. 2002, 296: 942-8.PubMedCrossRef
55.
Pour P, Althoff J, Kruger FW, Mohr U: A potent pancreatic carcinogen in Syrian hamsters: N-nitrosobis(2-oxopropyl)amine. J Natl Cancer Inst. 1977, 58 (5): 1449-53.PubMed
56.
Egami H, Takiyama Y, Chaney WG, Cano M, Fujii H, Tomioka T, Metzgar R, Pour PM: Comparative studies on expression of tumor-associated antigens in human and induced pancreatic cancer in Syrian hamsters. Int J Pancreatol. 1990, 7 (1–3): 91-100.PubMed
57.
Ishikawa O, Ohigashi H, Imaoka S, Nakai I, Mitsuo M, Weide L, Pour PM: The role of pancreatic islets in experimental pancreatic carcinogenicity. Am J Pathol. 1995, 147: 1456-64.PubMedCentralPubMed
58.
Takahashi M, Furukawa F, Toyoda K, Sato H, Hasegawa R, Imaida K, Hayashi Y: Effects of various prostaglandin synthesis inhibitors on pancreatic carcinogenesis in hamsters after initiation with N-nitrosobis(2-oxopropyl)amine. Carcinogenesis. 1990, 11 (3): 393-5.PubMedCrossRef
59.
Wenger FA, Kilian M, Achucarro P, Heinicken D, Schimke I, Guski H, Jacobi CA, Muller JM: Effects of Celebrex and Zyflo on BOP-induced pancreatic cancer in Syrian hamsters. Pancreatology. 2002, 2: 54-60.PubMedCrossRef
60.
Gunning WT, Kramer PM, Steele VE, Pereira MA: Chemoprevention by lipoxygenase and leukotriene pathway inhibitors of vinyl carbamate-induced lung tumors in mice. Cancer Res. 2002, 62: 4199-4201.PubMed
61.
Yano T, Zissel G, Muller-Qernheim J, Jae Shin S, Satoh H, Ichikawa T: Prostaglandin E2 reinforces the activation of Ras signal pathway in lung adenocarcinoma cells via EP3. FEBS Lett. 2002, 518: 154-158.PubMedCrossRef
62.
Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D, Tarnawski AS: Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med. 2002, 8: 289-293.PubMedCrossRef
63.
Fiebich BL, Schleicher S, Spleiss O, Czygan M, Hull M: Mechanisms of prostaglandin E2-induced interleukin-6 release in astrocytes: possible involvement of EP4-like receptors, p38 mitogen-activated protein kinase and protein kinase C:. J Neurochem. 2001, 79: 950-958.PubMedCrossRef
64.
Pai R, Szabo IL, Soreghan BA, Atay S, Kawanaka H, Tarnawski AS: PGE(2) stimulates VEGF expression in endothelial cells via ERK2/JNK1 signaling pathways. Biochem Biophys Res Commun. 2001, 286: 923-928.PubMedCrossRef
65.
Fujino H, West KA, Regan JW: Phosphorylation of glycogen synthase kinase-3 and stimulation of T-cell factor signaling following activation of EP2 and EP4 prostanoid receptors by prostaglandin E2. J Biol Chem. 2002, 277: 2614-2619.PubMedCrossRef
66.
Liu XH, Kirschenbaum A, Lu M, Yao S, Klausner A, Preston C, Holland JF, Levine AC: Prostaglandin E(2) stimulates prostatic intraepithelial neoplasia cell growth through activation of the interleukin-6/GP130/STAT-3 signaling pathway. Biochem Biophys Res Commun. 2002, 290: 249-255.PubMedCrossRef
67.
Bishop-Bailey D, Calatayud S, Warner TD, Hla T, Mitchell JA: Prostaglandins and the regulation of tumor growth. J Environ Pathol Toxicol Oncol. 2002, 21: 93-101.PubMedCrossRef
68.
Breyer RM: Prostaglandin EP(1) receptor subtype selectivity takes shape. Mol Pharmacol. 2001, 59: 1357-9.PubMed
69.
Sonoshita M, Takaku K, Sasaki N, Sugimoto Y, Ushikubi F, Narumiya S, Oshima M, Taketo MM: Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice. Nat Med. 2001, 7: 1048-51.PubMedCrossRef
70.
Rodrigues S, Nguyen QD, Faivre S, Bruyneel E, Thim L, Westley B, May F, Flatau G, Mareel M, Gespach C, Emami S: Activation of cellular invasion by trefoil peptides and src is mediated by cyclooxygenase- and thromboxane A2 receptor-dependent signaling pathways. FASEB J. 2001, 15: 1517-28.PubMedCrossRef
71.
Nie D, Lamberti M, Zacharek A, Li L, Szekeres K, Tang K, Chen Y, Honn KV: Thromboxane A(2) regulation of endothelial cell migration, angiogenesis, and tumor metastasis. Biochem Biophys Res Commun. 2000, 267: 245-51.PubMedCrossRef
72.
Kasahara K, Fujimura M, Bando T, Shibata K, Shirasaki H, Matsuda T: Modulation of sensitivity to cis-diamminedichloroplatinum (II) by thromboxane A2 receptor antagonists in non-small lung cell lines. Br J Cancer. 1996, 74: 1553-8.PubMedCentralPubMedCrossRef
73.
Rodrigues S, Nguyen QD, Faivre S, Bruyneel E, Thim L, Westley B, May F, Flatau G, Mareel M, Gespach C, Emami S: Activation of cellular invasion by trefoil peptides and src is mediated by cyclooxygenase- and thromboxane A2 receptor-dependent signaling pathways. FASEB J. 2001, 15: 1517-28.PubMedCrossRef
74.
Fujimura M, Kasahara K, Shirasaki H, Heki U, Iwasa K, Ueda A, Matsuda T: Up-regulation of ICH-1L protein by thromboxane A2 antagonists enhances cisplatin-induced apoptosis in non-small-cell lung-cancer cell lines. J Cancer Res Clin Oncol. 1999, 125: 389-94.PubMedCrossRef
75.
Pakala R, Benedict CR: Effect of serotonin and thromboxane A2 on endothelial cell proliferation: effect of specific receptor antagonists. J Lab Clin Med. 1998, 131: 527-37.PubMedCrossRef
76.
Ding XZ, Tong WG, Adrian TE: 12-lipoxygenase metabolite, 12(S)-HETE stimulates pancreatic cancer cell proliferation. Involvement of tyrosine phosphorylation and MEK/ERK activation. Int J Cancer. 2001, 94: 630-636.PubMedCrossRef
77.
Ding XZ, Tong WG, Adrian TE: Interaction between the 5-lipoxygenase and EGF-mediated signaling pathways is important in the control of pancreatic cancer cell proliferation. Pancreas. 2001, 23: 434-
78.
Adrian TE, Ding XZ, Tong WG: The mitogenic effect of 5-lipoxygenase metabolite, 5-HETE on pancreatic cancer cell proliferation through activation of multiple signaling pathways. FASEB J. 2001, 15: A1163-
79.
Tong WG, Ding XZ, Hennig R, Witt RC, Standop J, Pour PM, Adrian TE: Leukotriene B4 Receptor Antagonist LY293111 Inhibits Proliferation and Induces Apoptosis in Human Pancreatic Cancer Cells. Clin Cancer Res. 2002, 8: 3232-3242.PubMed
80.
Szekeres CK, Tang K, Trikha M, Honn KV: Eicosanoid activation of extracellular signal-regulated kinase1/2 in human epidermoid carcinoma cells. J Biol Chem. 2000, 275: 38831-3841.PubMedCrossRef
81.
Liu B, Maher RJ, De Jonckheere JP, Popat RU, Stojakovic S, Hannun YA, Porter AT, Honn KV: 12(S)-HETE increases the motility of prostate tumor cells through selective activation of PKC alpha. Adv Exp Med Biol. 1997, 400B: 707-718.PubMed
82.
Liu B, Khan WA, Hannun YA, Timar J, Taylor JD, Lundy S, Butovich I, Honn KV: 12(S)-hydroxyeicosatetraenoic acid and 13(S)-hydroxyoctadecadienoic acid regulation of protein kinase C-alpha in melanoma cells: role of receptor-mediated hydrolysis of inositol phospholipids. Proc Natl Acad Sci U S A. 1995, 92: 9323-9327.PubMedCentralPubMedCrossRef
83.
Li M, Wu X, Xu XC: Induction of apoptosis by cyclo-oxygenase-2 inhibitor NS398 through a cytochrome C-dependent pathway in esophageal cancer cells. Int J Cancer. 2001, 93: 218-23.PubMedCrossRef
84.
Li M, Wu X, Xu XC: Induction of apoptosis in colon cancer cells by cyclooxygenase-2 inhibitor NS398 through a cytochrome c-dependent pathway. Clin Cancer Res. 2001, 7: 1010-6.PubMed
85.
Aggarwal S, Taneja N, Lin L, Orringer MB, Rehemtulla A, Beer DG: Indomethacin-induced apoptosis in esophageal adenocarcinoma cells involves upregulation of Bax and translocation of mitochondrial cytochrome C independent of COX-2 expression. Neoplasia. 2000, 2 (4): 346-56.PubMedCentralPubMedCrossRef
86.
Munkarah AR, Morris R, Baumann P, Deppe G, Malone J, Diamond MP, Saed GM: Effects of prostaglandin E(2) on proliferation and apoptosis of epithelial ovarian cancer cells. J Soc Gynecol Investig. 2002, 9: 168-73.PubMedCrossRef
87.
Lin MT, Lee RC, Yang PC, Ho FM, Kuo ML: Cyclooxygenase-2 inducing Mcl-1-dependent survival mechanism in human lung adenocarcinoma CL1.0 cells. Involvement of phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem. 2001, 276: 48997-9002.PubMedCrossRef
88.
Nzeako UC, Guicciardi ME, Yoon JH, Bronk SF, Gores GJ: COX-2 inhibits Fas-mediated apoptosis in cholangiocarcinoma cells. Hepatology. 2002, 35: 552-9.PubMedCrossRef
89.
Tang X, Sun YJ, Half E, Kuo MT, Sinicrope F: Cyclooxygenase-2 overexpression inhibits death receptor 5 expression and confers resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human colon cancer cells. Cancer Res. 2002, 62: 4903-8.PubMed
90.
He Q, Luo X, Huang Y, Sheikh MS: Apo2L/TRAIL differentially modulates the apoptotic effects of sulindac and a COX-2 selective non-steroidal anti-inflammatory agent in Bax-deficient cells. Oncogene. 2002, 21: 6032-40.PubMedCrossRef
91.
Chan TA: Nonsteroidal anti-inflammatory drugs, apoptosis, and colon-cancer chemoprevention. Lancet Oncol. 2002, 3: 166-74.PubMedCrossRef
92.
Thun MJ, Henley SJ, Patrono C: Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst. 2002, 94: 252-66.PubMedCrossRef
93.
Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS: The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem. 2000, 275: 11397-403.PubMedCrossRef
94.
Shimada T, Hiraishi H, Terano A: Hepatocyte growth factor protects gastric epithelial cells against ceramide-induced apoptosis through induction of cyclooxygenase-2. Life Sci. 2000, 68: 539-46.PubMedCrossRef
95.
Chan TA, Morin PJ, Vogelstein B, Kinzler KW: Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci U S A. 1998, 95: 681-6.PubMedCentralPubMedCrossRef
96.
Pidgeon GP, Kandouz M, Meram A, Honn KV: Mechanisms controlling cell cycle arrest and induction of apoptosis after 12-lipoxygenase inhibition in prostate cancer cells. Cancer Res. 2002, 62: 2721-7.PubMed
97.
Wong BC, Wang WP, Cho CH, Fan XM, Lin MC, Kung HF, Lam SK: 12-Lipoxygenase inhibition induced apoptosis in human gastric cancer cells. Carcinogenesis. 2001, 22: 1349-54.PubMedCrossRef
98.
Tang DG, Chen YQ, Honn KV: Arachidonate lipoxygenases as essential regulators of cell survival and apoptosis. Proc Natl Acad Sci U S A. 1996, 93: 5241-6.PubMedCentralPubMedCrossRef
99.
Rozic JG, Chakraborty C, Lala PK: Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis. Int J Cancer. 2001, 93: 497-506.PubMedCrossRef
100.
Sheng H, Shao J, Washington MK, DuBois RN: Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem. 2001, 276: 18075-81.PubMedCrossRef
101.
Gately S: The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Rev. 2000, 19: 19-27.PubMedCrossRef
102.
Pan MR, Chuang LY, Hung WC: Non-steroidal anti-inflammatory drugs inhibit matrix metalloproteinase-2 expression via repression of transcription in lung cancer cells. FEBS Lett. 2001, 508: 365-8.PubMedCrossRef
103.
Jiang MC, Liao CF, Lee PH: Aspirin inhibits matrix metalloproteinase-2 activity, increases E-cadherin production, and inhibits in vitro invasion of tumor cells. Biochem Biophys Res Commun. 2001, 282: 671-7.PubMedCrossRef
104.
Attiga FA, Fernandez PM, Weeraratna AT, Manyak MJ, Patierno SR: Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Res. 2000, 60: 4629-37.PubMed
105.
Fosslien E: Review: molecular pathology of cyclooxygenase-2 in cancer-induced angiogenesis. Ann Clin Lab Sci. 2001, 31: 325-48.PubMed
106.
Gately S: The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Rev. 2000, 19 (1–2): 19-27.PubMedCrossRef
107.
Masferrer JL, Koki A, Seibert K: COX-2 inhibitors. A new class of antiangiogenic agents. Ann N Y Acad Sci. 1999, 889: 84-6.PubMedCrossRef
108.
Sonoshita M, Takaku K, Sasaki N, Sugimoto Y, Ushikubi F, Narumiya S, Oshima M, Taketo MM: Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice. Nat Med. 2001, 7: 1048-51.PubMedCrossRef
109.
Daniel TO, Liu H, Morrow JD, Crews BC, Marnett LJ: Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis. Cancer Res. 1999, 59: 4574-7.PubMed
110.
Spisni E, Griffoni C, Santi S, Riccio M, Marulli R, Bartolini G, Toni M, Ullrich V, Tomasi V: Colocalization prostacyclin (PGI2) synthase – caveolin-1 in endothelial cells and new roles for PGI2 in angiogenesis. Exp Cell Res. 2001, 266: 31-43.PubMedCrossRef
111.
Ali S, Davis MG, Becker MW, Dorn GW: Thromboxane A2 stimulates vascular smooth muscle hypertrophy by up-regulating the synthesis and release of endogenous basic fibroblast growth factor. J Biol Chem. 1993, 268: 17397-403.PubMed
112.
Chen G, Wilson R, McKillop JH, Walker JJ: The role of cytokines in the production of prostacyclin and thromboxane in human mononuclear cells. Immunol Invest. 1994, 23: 269-79.PubMedCrossRef
113.
Bartolini G, Orlandi M, Chiricolo M, Minghetti L, Guerrini F, Fidan M, Franceschi C, Tomasi V: Regulation of thromboxane A2 biosynthesis in platelet-free human monocytes and the possible role of polypeptide growth factor(s) in the induction of cyclooxygenase system. Biochim Biophys Acta. 1986, 876: 486-93.PubMedCrossRef
114.
Dethlefsen SM, Shepro D, D'Amore PA: Arachidonic acid metabolites in bFGF-, PDGF-, and serum-stimulated vascular cell growth. Exp Cell Res. 1994, 12: 262-73.CrossRef
115.
Nie D, Tang K, Diglio C, Honn KV: Eicosanoid regulation of angiogenesis: role of endothelial arachidonate 12-lipoxygenase. Blood. 2000, 95: 2304-11.PubMed
116.
Nie D, Tang K, Szekeres K, Li L, Honn KV: Eicosanoid regulation of angiogenesis in human prostate carcinoma and its therapeutic implications. Ann N Y Acad Sci. 2000, 905: 165-76.PubMedCrossRef
117.
Nie D, Hillman GG, Geddes T, Tang K, Pierson C, Grignon DJ, Honn KV: Platelet-type 12-lipoxygenase regulates angiogenesis in human prostate carcinoma. Adv Exp Med Biol. 1999, 469: 623-30.PubMedCrossRef
118.
Nie D, Hillman GG, Geddes T, Tang K, Pierson C, Grignon DJ, Honn KV: Platelet-type 12-lipoxygenase in a human prostate carcinoma stimulates angiogenesis and tumor growth. Cancer Res. 1998, 58: 4047-51.PubMed
119.
120.
Goodwin JS, Ceuppens J: Regulation of the immune response by prostaglandins. J Clin Immunol. 1983, 3: 295-315.PubMedCrossRef
121.
Ceuppens J, Goodwin J: Prostaglandins and the immune response to cancer. Anticancer Res. 1981, 1: 71-8.PubMed
122.
Farrow B, Evers BM: Inflammation and the development of pancreatic cancer. Surg Oncol. 2002, 10: 153-69.PubMedCrossRef
123.
Joshi PC, Zhou X, Cuchens M, Jones Q: Prostaglandin E2 suppressed IL-15-mediated human NK cell function through down-regulation of common gamma-chain. J Immunol. 2001, 166: 885-91.PubMedCrossRef
124.
Lala PK, Chakraborty C: Role of nitric oxide in carcinogenesis and tumour progression. Lancet Oncol. 2001, 2: 149-56.PubMedCrossRef
125.
Jadeski LC, Hum KO, Chakraborty C, Lala PK: Nitric oxide promotes murine mammary tumour growth and metastasis by stimulating tumour cell migration, invasiveness and angiogenesis. Int J Cancer. 2000, 86: 30-9.PubMedCrossRef
126.
Kong G, Kim EK, Kim WS, Lee KT, Lee YW, Lee JK, Paik SW, Rhee JC: Role of cyclooxygenase-2 and inducible nitric oxide synthase in pancreatic cancer. J Gastroenterol Hepatol. 2002, 17: 914-21.PubMedCrossRef
127.
de Ledinghen V, Liu H, Zhang F, Lo CR, Subbaramaiah K, Dannenberg AJ, Czaja MJ: Induction of cyclooxygenase-2 by tumor promoters in transformed and cytochrome P450 2E1-expressing hepatocytes. Carcinogenesis. 2002, 23: 73-9.PubMedCrossRef
128.
Keith RL, Miller YE, Hoshikawa Y, Moore MD, Gesell TL, Gao B, Malkinson AM, Golpon HA, Nemenoff RA, Geraci MW: Manipulation of pulmonary prostacyclin synthase expression prevents murine lung cancer. Cancer Res. 2002, 62: 734-40.PubMed
129.
Degen GH: SEMV cell cultures: a model for studies of prostaglandin-H synthase-mediated metabolism and genotoxicity of xenobiotics. Toxicol Lett. 1993, 67: 187-200.PubMedCrossRef
130.
Marnett LJ: Prostaglandin synthase-mediated metabolism of carcinogens and a potential role for peroxyl radicals as reactive intermediates. Environ Health Perspect. 1990, 88: 5-12.PubMedCentralPubMedCrossRef
131.
Schuller HM, Zhang L, Weddle DL, Castonguay A, Walker K, Miller MS: The cyclooxygenase inhibitor ibuprofen and the FLAP inhibitor MK886 inhibit pancreatic carcinogenesis induced in hamsters by transplacental exposure to ethanol and the tobacco carcinogen NNK. J Cancer Res Clin Oncol. 2002, 128: 525-32.PubMedCrossRef
132.
Castonguay A, Rioux N, Duperron C, Jalbert G: Inhibition of lung tumorigenesis by NSAIDS: a working hypothesis. Exp Lung Res. 1998, 24: 605-15.PubMedCrossRef
133.
Schuller HM, Tithof PK, Williams M, Plummer H: The tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone is a beta-adrenergic agonist and stimulates DNA synthesis in lung adenocarcinoma via beta-adrenergic receptor-mediated release of arachidonic acid. Cancer Res. 1999, 59: 4510-5.PubMed
134.
Smith TJ, Stoner GD, Yang CS: Activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in human lung microsomes by cytochromes P450, lipoxygenase, and hydroperoxides. Cancer Res. 1995, 55: 5566-73.PubMed
135.
Bhat KP, Pezzuto JM: Cancer chemopreventive activity of resveratrol. Ann N Y Acad Sci. 2002, 957: 210-29.PubMedCrossRef
136.
Dirsch VM, Vollmar AM: Ajoene, a natural product with non-steroidal anti-inflammatory drug (NSAID)-like properties. Biochem Pharmacol. 2001, 61: 587-93.PubMedCrossRef
137.
Pinto JT, Lapsia S, Shah A, Santiago H, Kim G: Antiproliferative effects of garlic-derived and other allium related compounds. Adv Exp Med Biol. 2001, 492: 83-106.PubMedCrossRef
138.
Yang CS, Maliakal P, Meng X: Inhibition of carcinogenesis by tea. Annu Rev Pharmacol Toxicol. 2002, 42: 25-54.PubMedCrossRef
139.
Wargovich MJ, Woods C, Hollis DM, Zander ME: Herbals, cancer prevention and health. J Nutr. 2001, 131 (11 Suppl): 3034S-6S.PubMed
140.
Hwang DH, Fung V, Dannenberg AJ: National Cancer Institute workshop on chemopreventive properties of nonsteroidal anti-inflammatory drugs: role of COX-dependent and -independent mechanisms. Neoplasia. 2002, 4: 91-97.PubMedCentralPubMedCrossRef
Metadata
Title
Lipoxygenase and cyclooxygenase metabolism: new insights in treatment and chemoprevention of pancreatic cancer
Authors
Xian-Zhong Ding
Rene Hennig
Thomas E Adrian
Publication date
01-12-2003
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2003
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-2-10

Other articles of this Issue 1/2003

Molecular Cancer 1/2003 Go to the issue

Review

Invasion and metastasis in pancreatic cancer

Research

Association of Ataxia Telangiectasia Mutated (ATM) gene mutation/deletion with Rhabdomyosarcoma

Research

Analysis of VEGF-responsive Genes Involved in the activation of endothelial cells

Research

SLC/CCL21-mediated anti-tumor responses require IFNγ, MIG/CXCL9 and IP-10/CXCL10

Short communication

Regulation of COX-2 transcription in a colon cancer cell line by Pontin52/TIP49a

Research

Expression of biomarkers modulating prostate cancer angiogenesis: Differential expression of annexin II in prostate carcinomas from India and USA
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits